Korean biotech company liable in gene therapy dispute
A Korean biotech company has been ordered to pay US$40 million in an ICC arbitration over the mislabelling of a gene therapy treatment, a matter that caused a scandal in Korea and led to the prosecution of executives.
To read more
Subscribe to Global Arbitration Review
Subscribe and start reading now
Global Arbitration Review (GAR) is the online home for international arbitration specialists, telling them everything they need to know about all the developments that matter.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10